Klinipharm GmbH, Eschborn
Klinipharm GmbH, Eschborn
Klinipharm GmbH, Eschborn

Empfehlen Sie uns weiter

Teilen Sie unsere Internetseite mit Ihren Freunden.
Klinipharm GmbH, Eschborn


Our Team

Wolfgang Schatton, Ph.D.

Co-Founder, Chairman, and CSO

Dr. Wolfgang Schatton co-founded KliniPharm in 1993 to address the lack of technologically innovative natural products based on the latest scientific research. His distinguished career in the pharmaceutical industry includes over 15 years as head of R&D at Merz Pharmaceuticals and Pascoe Naturmedizin and a successful track record for developing and bringing drugs to the market. Dr. Schatton has been responsible for numerous pharmaceutical product approvals and new product launches in the fields of tumor angiogenesis, infectious, cardiovascular, and neurodegenerative disease – most notably the multi-billion dollar blockbuster Namenda™ (Axura®, Memantine) while Head of R&D at Merz. His expertise in scientific research, managerial planning, and development and manufacturing of pharmaceuticals from all-natural bioactive ingredients has been a tremendous asset to KliniPharm.

Dr. Schatton earned his doctoral degree in Pharmacology and Medicinal Chemistry from the University of Frankfurt, Germany. He has held several academic appointments as an adjunct professor, has led numerous research projects, and authored over 30 scholarly articles and patents. His ties to industry and academia have been instrumental in forming collaborations with corporate partners and scientific institutions throughout the European Union, from which KliniPharm’s patents, product prototypes, and product developments have emerged.

Maria Schatton

Co-Founder and CEO

Mrs. Schatton co-founded KliniPharm with Dr. Wolfgang Schatton in 1993. With over ten years of experience in project planning and coordination with Greek governmental organizations, she has been instrumental in providing strategic vision for KliniPharm’s growth, setting up international partnerships between Greece, Germany, and scientific institutes throughout Europe, and facilitating the establishment of KliniPharm’s sustainable sponge farms. Mrs. Schatton was recognized by the Greek-German Economic Association in 2003 for her strategic leadership in advancing economic relations between Greece and Germany and helping further the progress of marine research. She continues to drive KliniPharm’s growth through expansion initiatives with corporate partners, academic institutions, and European governmental organizations.

Mrs. Schatton graduated in International Relations from Pantios University, Athens, Greece, and received postgraduate training in Political Science at the Collège de Sorbonne in Paris, France, and the University of Frankfurt, Germany.

Tobias Schatton, Pharm.D., Ph.D.

Partner and Scientific Advisor

Dr. Tobias Schatton joined KliniPharm in 2001 and has focused on the strategic positioning of KliniPharm’s R&D activities, coordination with academic and corporate partners, and development of the product portfolio. He has been a prime mover of eleana™, KliniPharm’s skin care and wellness line. Dr. Schatton has expertise in drug delivery research as well as basic and translational scientific research with a specific emphasis on skin-associated stem cells and their role in immunity, tissue regeneration, and tumor development.

Dr. Schatton holds a Pharm.D. degree from the University of Frankfurt, Germany, and a Ph.D. degree in Biochemistry from the University of Würzburg, Germany, based on research conducted during a Research Fellowship at Harvard Medical School. He is currently an Assistant Professor of Dermatology at Harvard Medical School and a Research Associate of the Department of Dermatology at Brigham and Women’s Hospital , Boston, MA, USA. He has been the recipient of numerous awards, fellowships, and research grants and has published articles in leading scientific journals, including Nature and Cell.

Jan Lennertz

Business Advisor

Jan Lennertz serves as business advisor to KliniPharm providing advice in areas such as marketing strategy, finances or collaboration strategy and has been an important sounding board to KliniPharm.

Mr. Lennertz holds a Diplom Kaufmann (MBA equivalent) from the European Business School, Oestrich-Winkel, Germany, as well as a Master of Business Administration from the University of Pittsburgh, USA. He is currently an Executive Director in Morgan Stanley’s Mergers & Acquisitions Department in New York. During his career at Morgan Stanley, he has also worked as a generalist in its Frankfurt, Germany office and as a member of the Consumer / Retail Industry Team in New York. He has advised on ~$150Bn in completed M&A and financing transactions across a variety of industries, including consumer, retail, and healthcare.